Renalytix Plc (NASDAQ:RNLX) Short Interest Update

Renalytix Plc (NASDAQ:RNLX) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 3,050,000 shares, an increase of 941.3% from the June 30th total of 292,900 shares. Based on an average daily trading volume, of 1,760,000 shares, the short-interest ratio is currently 1.7 days.

Hedge Funds Weigh In On Renalytix

An institutional investor recently raised its position in Renalytix stock. Pinnacle Associates Ltd. lifted its stake in shares of Renalytix Plc (NASDAQ:RNLX) by 7.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 846,534 shares of the company’s stock after acquiring an additional 60,572 shares during the quarter. Pinnacle Associates Ltd. owned approximately 1.69% of Renalytix worth $330,000 at the end of the most recent reporting period. 9.92% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Renalytix in a research report on Friday, July 12th.

Renalytix Stock Up 3.9 %

Renalytix stock traded up $0.01 during midday trading on Thursday, reaching $0.31. The stock had a trading volume of 135,470 shares, compared to its average volume of 1,682,897. Renalytix has a 52-week low of $0.22 and a 52-week high of $3.30. The firm has a market cap of $23.58 million, a price-to-earnings ratio of -0.78 and a beta of 2.78. The company has a fifty day moving average of $0.38 and a 200 day moving average of $0.60.

Renalytix (NASDAQ:RNLX) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.08) earnings per share for the quarter. Renalytix had a negative return on equity of 1,008.88% and a negative net margin of 1,687.80%. The firm had revenue of $0.54 million during the quarter. Equities research analysts predict that Renalytix will post -0.3 EPS for the current year.

Renalytix Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.